公开(公告)号：WO2017197390A1

公开(公告)日：2017-11-16

申请号：PCT/US2017/032669

申请日：2017-05-15

Applicant: SPERO POTENTIATOR, INC.

Inventor： COLEMAN, Scott ,  SHASTRI, Prathap N.

IPC: A61K38/12 ,  A61K38/14 ,  A61K45/06 ,  A61K31/351 ,  A61K31/407 ,  A61K31/46 ,  A61K31/496 ,  A61K31/575 ,  A61K31/7048 ,  A61K31/7052 ,  A61P31/04

CPC classification number: A61K38/12 ,  A61K9/0019 ,  A61K31/351 ,  A61K31/407 ,  A61K31/46 ,  A61K31/496 ,  A61K31/575 ,  A61K31/7048 ,  A61K31/7052 ,  A61K38/14 ,  A61K45/06 ,  A61P31/04 ,  Y02A50/473 ,  A61K2300/00

Abstract: This disclosure provides a method of treating a bacterial infection in a human patient comprising by administering a therapeutically effective dose of SPR741, a polymyxin analog, in combination with a therapeutically effective amount of an antibiotic other than SPR741. The disclosure establishes 100 mg to 500 mg of SPR741, administered 2 to 4 times daily as the effective amount of SPR741 for co-administration with a therapeutically effective amount of a second antibiotic. The disclosure also provides a method of treating a bacterial infection comprising administering 40 mg/ kg patient weight/ day or less and preferably 5 mg/ kg patient weight/ day or less of SPR741 in combination with a therapeutically effective amount of a second antibiotic.

Abstract translation: 本公开内容提供了治疗人类患者的细菌感染的方法，其包括通过施用治疗有效剂量的SPR741（多粘菌素类似物）与治疗有效量的除SPR741以外的抗生素组合。 本公开建立了100mg至500mg的SPR741，每日施用2至4次作为与治疗有效量的第二抗生素共同施用的SPR741的有效量。 本公开还提供了治疗细菌感染的方法，其包括与治疗有效量的第二抗生素组合施用40mg / kg患者体重/天或更少，优选5mg / kg患者体重/天或更少的SPR741。 / p>